Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Ecancermedicalscience ; 15: 1168, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33680082

RESUMO

BACKGROUND: Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are needed. Perioperative chemotherapies show improvement in pathological complete remission (pCR) and overall survival (OS), but less than 50% of the patients completed the chemotherapeutic regimen. The recent 5-fluorouracil, leucovorin, oxaliplatin, docetaxel-4 (FLOT4) study shows OS 50 months and pCR 16.6%, but only 46% of the patients completed pre- and postoperative treatment. This case series report evaluated pCR and safety in patients that received complete preoperative chemotherapeutic with FLOT. METHODS: Patients received eight cycles FLOT regimen before surgery. Each cycle comprised 50 mg/m2 docetaxel intravenous (iv) on day 1, 85 mg/m2 oxaliplatin iv on day 1, 200 mg/m2 leucovorin iv on day 1 and 2,600 mg/m2 5-fluorouracil iv in a 24-hour infusion on day 1, every 2 weeks. RESULTS: Fifty-nine patients were evaluated, 58 patients received preoperative cycles. Thirty-one patients received all eight cycles of preoperative therapy. 65.5% patients presented any major adverse event. Thirty-nine patients underwent surgery. Thirty-three biopsy reports were obtained. Six patients (18.2%) presented pCR, 13 patients (39.4%) had no lymph node involvement. OS was 21.32 months. Patients with histology of signet ring carcinoma cells had a shorter survival than other histologies. CONCLUSION: Total neoadjuvant with FLOT chemotherapy presents an adequate safety profile, a similar pathologic regression rate, and a slightly higher rate of completing treatment to report in perioperative FLOT regimen studies. A prospective clinical study with suitable diagnostic, staging tools and an adequate follow-up may prove total neoadjuvant chemotherapy's efficacy.

2.
J Surg Oncol ; 93(8): 699-704, 2006 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-16724351

RESUMO

Gallbladder cancer (GC) is considered a rare disease associated with a poor prognosis. Unfortunately, the low number of cases makes the performance of trials addressing the role of adjuvant, neoadjuvant, and/or palliative therapy difficult. For a long time, the majority of trials were 5-fluorouracil (5 FU)-based, and results were uniformly poor. Since the introduction of Gemcitabine, response rates of approximately 30% have been observed through the use of this drug and new approaches have been tested. In this sense, drugs such as Cisplatin and Capecitabine have been employed concurrently with gemcitabine and/or radiation. Since a recurrence pattern is both distant and local, chernoradiation seems a logical option to deal with the disease. However, at the present time, the lack of valid and scientific evidence means that most of the recommendations originate from trials dealing with other tumors, such as pancreas cancer and biliary tract cancer (BTC). The aforementioned treatment alternatives warrant further evaluation focusing on GC.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Vesícula Biliar/tratamento farmacológico , Neoplasias da Vesícula Biliar/radioterapia , Antimetabólitos Antineoplásicos/administração & dosagem , Neoplasias do Sistema Biliar/tratamento farmacológico , Neoplasias do Sistema Biliar/radioterapia , Capecitabina , Cisplatino/administração & dosagem , Terapia Combinada , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Feminino , Fluoruracila/administração & dosagem , Neoplasias da Vesícula Biliar/patologia , Neoplasias da Vesícula Biliar/cirurgia , Humanos , Masculino , Terapia Neoadjuvante , Cuidados Paliativos , Análise de Sobrevida , Gencitabina
3.
Rev Med Chil ; 131(11): 1301-4, 2003 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-14743692

RESUMO

We report a 67 years old woman admitted to the hospital for the study of a cholestatic jaundice and massive hepatomegaly. On admission, the patient did not have liver failure. During hospital stay, the patient experienced a progressive deterioration of liver function and a monoclonal gammopathy was detected. An IgG Kappa myeloma-was diagnosed. A fine needle liver biopsy disclosed the presence of amyloid. The patient developed acute liver failure and died three weeks after admission.


Assuntos
Amiloidose/complicações , Falência Hepática Aguda/etiologia , Mieloma Múltiplo/complicações , Idoso , Amiloidose/patologia , Biópsia por Agulha , Evolução Fatal , Feminino , Humanos , Imunoglobulina G , Mieloma Múltiplo/patologia , Paraproteinemias/complicações
4.
Bol. Hosp. San Juan de Dios ; 54(1): 48-52, ene.-feb. 2007. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-464594

RESUMO

Los tumores del estroma gastrointestinal (GIST) son neoplasias de baja frecuencia que presentan menos del 1 por ciento de todos los tumores del tracto digestivo. Inicialmente se clasificaban dentro del grupo de los sarcomas pero actualmente se consideran como una entidad clínico patológica diferente. Comprometen con mayor frecuencia el estómago pero se pueden presentar en cualquier otra ubicación del tracto digestivo donde exista músculo liso. Su diagnóstico es histológico. El 80 por ciento de estos tumores expresa CD 117 y el 20 por ciento restante tiene mutaciones en un receptor de Tirosina-Kinasa (TK) relacionado con PDGFRa (platelet-derived growth factor receptor alpha). El tratamiento se basa en cirugía y administración de inhibidores de Tirosina-Kinasa. En este trabajo se presentan tres casos clínicos de GIST del aparato digestivo. CD 117 positivos. Se revisan los aspectos fisiopatológicos, clínicos, diagnóstico y terapéuticos de este tipo especial de tumores.


Assuntos
Masculino , Feminino , Pessoa de Meia-Idade , Humanos , Tumores do Estroma Gastrointestinal/diagnóstico , Diagnóstico Diferencial , Tumores do Estroma Gastrointestinal/fisiopatologia , Tumores do Estroma Gastrointestinal/terapia
5.
Bol. Hosp. San Juan de Dios ; 48(2): 212-8, mar.-abr. 2001. ilus
Artigo em Espanhol | LILACS | ID: lil-296100

RESUMO

El síndrome de Q-T largo es la descripción fenotípica de un grupo de trastornos caracterizados por un intervalo Q-T prolongado en el Electrocardiograma, asociado al riesgo de desarrollar una arritmia característica, la taquicardia ventricular polimórfica (helicoidal) conocida como Torsión de las puntas. El síndrome del Q-T largo puede ser congénito, asociado o no a otras alteraciones, o bien, adquirido, fundamentalmente en relación con drogas. Si bien se trata de una afección de baja incidencia, el estudio de sus bases fisiopatológicas ha permitido conocer profundamente las bases moleculares de los fenómenos eléctricos del corazón.Dada su baja frecuencia y, lo inespecífico y potencialmente grave de sus manifestaciones, es que su sospecha es fundamental para un adecuado diagnóstico y manejo, siendo el electrocardiograma convencional una herramienta fundamental en el diagnóstico. El manejo de los pacientes se basa fundamentalmente en la indicación de betabloqueadores, el uso de marcapasos y, en algunos casos, de desfribilador implantable. Se presenta el caso clínico de una mujer joven con una larga historia de síncopes, en la que finalmente se llega al diagnóstico de síndrome del Q-T largo, muy probablemente congénito


Assuntos
Humanos , Feminino , Adulto , Síndrome do QT Longo/diagnóstico , Síndrome do QT Longo/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA